Bernard Davitian

Partner

Bernard joined Omega Funds in 2020. He has extensive experience in the pharma and biotech industry, marked by a number of successful transactions involving financings and M&A. Bernard currently serves on the Board of Directors of Endeavor BioMedicines and Vanqua Bio. Bernard was previously a board member of EyeBio (acquired by Merck & Co in July 2024), Upstream Bio (Nasdaq: UPB), and Lexeo Therapeutics (Nasdaq: LXEO).

Bernard previously served as SVP and Managing Director at Sanofi Ventures, having first joined Sanofi in 2010 as Vice President, Deputy Global Head, Business Development. Over his 7-year tenure, Sanofi Ventures invested in 28 new companies and generated 14 exits (12 Nasdaq IPOs, 1 trade sale and 1 option deal).

Prior to Sanofi, Bernard held CEO, CFO and other leadership roles at Fovea Pharmaceuticals (which was acquired by Sanofi in 2009 in a $540 million cash transaction), Neurotech Pharmaceuticals, Transgene (which successfully raised $100 million in a 1998 IPO on the NASDAQ/EuroNext) and Institut Mérieux (now Sanofi Pasteur).